Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation
Background Critically ill patients often experience several transitions of care following critical illness. Research has explored the challenges which patients have with medication management across these transitions. It is unclear whether patients admitted to critical care due to COVID-19 will have...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-01-01
|
| Series: | BMJ Open Respiratory Research |
| Online Access: | https://bmjopenrespres.bmj.com/content/8/1/e001037.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162601261006848 |
|---|---|
| author | Martin Shaw Tara Quasim Pamela MacTavish Rakesh Kishore Joanne McPeake Ruth Forrest Antoin Breslin Fiona MacGregor Alison Oprey |
| author_facet | Martin Shaw Tara Quasim Pamela MacTavish Rakesh Kishore Joanne McPeake Ruth Forrest Antoin Breslin Fiona MacGregor Alison Oprey |
| author_sort | Martin Shaw |
| collection | DOAJ |
| description | Background Critically ill patients often experience several transitions of care following critical illness. Research has explored the challenges which patients have with medication management across these transitions. It is unclear whether patients admitted to critical care due to COVID-19 will have similar challenges. The aim of this study was to explore medication management in critical care survivors following severe COVID-19.Methods Between 3 and 7 months post hospital discharge, patients who had been admitted to critical care due to severe COVID-19 were invited to an established recovery service. During the clinic consultation a medication review was performed by a pharmacist. This included medicines reconciliation, assessing the appropriateness of each of the prescribed medications and identification of medication changes. We also assessed changes to pain management in the discharge period.Results In total, 78 patients had a full medication review available. Over 70% of patients were taking an increased dose of medicine or a new medicine at clinic. There was a significant overall increase in new medication during the clinic consultation, across different British National Formulary classifications (OR: 1.73 (95% CI: 1.28 to 2.34), p<0.001). Compared with pre critical care admission, there was a significant increase in the number of patients taking regular analgesia following severe COVID-19 infection (23 (29.5%) vs 39 (50%), p<0.001).Conclusion Following severe COVID-19, patients may require new or increasing doses of medicines. Ongoing review of these patients is crucial to ensure optimal outcomes. |
| format | Article |
| id | doaj-art-552090319c654d359cc91af506c0b60e |
| institution | OA Journals |
| issn | 2052-4439 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Respiratory Research |
| spelling | doaj-art-552090319c654d359cc91af506c0b60e2025-08-20T02:22:32ZengBMJ Publishing GroupBMJ Open Respiratory Research2052-44392021-01-018110.1136/bmjresp-2021-001037Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluationMartin Shaw0Tara Quasim1Pamela MacTavish2Rakesh Kishore3Joanne McPeake4Ruth Forrest5Antoin Breslin6Fiona MacGregor7Alison Oprey8School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G31 2ER, UKAnaesthesia & Critical Care, Glasgow Royal Infirmary, Glasgow, UK1 NHS Greater Glasgow and Clyde, Glasgow, UKIntensive Care Unit, NHS Greater Glasgow and Clyde, Glasgow, UKNHS Greater Glasgow and Clyde, Glasgow, UKIntensive Care Unit, Queen Elizabeth University Hospital, Glasgow, UKSchool of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UKRoyal Alexandra Hospital, NHS Greater Glasgow and Clyde, Glasgow, UKQueen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UKBackground Critically ill patients often experience several transitions of care following critical illness. Research has explored the challenges which patients have with medication management across these transitions. It is unclear whether patients admitted to critical care due to COVID-19 will have similar challenges. The aim of this study was to explore medication management in critical care survivors following severe COVID-19.Methods Between 3 and 7 months post hospital discharge, patients who had been admitted to critical care due to severe COVID-19 were invited to an established recovery service. During the clinic consultation a medication review was performed by a pharmacist. This included medicines reconciliation, assessing the appropriateness of each of the prescribed medications and identification of medication changes. We also assessed changes to pain management in the discharge period.Results In total, 78 patients had a full medication review available. Over 70% of patients were taking an increased dose of medicine or a new medicine at clinic. There was a significant overall increase in new medication during the clinic consultation, across different British National Formulary classifications (OR: 1.73 (95% CI: 1.28 to 2.34), p<0.001). Compared with pre critical care admission, there was a significant increase in the number of patients taking regular analgesia following severe COVID-19 infection (23 (29.5%) vs 39 (50%), p<0.001).Conclusion Following severe COVID-19, patients may require new or increasing doses of medicines. Ongoing review of these patients is crucial to ensure optimal outcomes.https://bmjopenrespres.bmj.com/content/8/1/e001037.full |
| spellingShingle | Martin Shaw Tara Quasim Pamela MacTavish Rakesh Kishore Joanne McPeake Ruth Forrest Antoin Breslin Fiona MacGregor Alison Oprey Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation BMJ Open Respiratory Research |
| title | Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation |
| title_full | Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation |
| title_fullStr | Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation |
| title_full_unstemmed | Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation |
| title_short | Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation |
| title_sort | evaluation of medication changes following severe covid 19 infection a multicentre evaluation |
| url | https://bmjopenrespres.bmj.com/content/8/1/e001037.full |
| work_keys_str_mv | AT martinshaw evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT taraquasim evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT pamelamactavish evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT rakeshkishore evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT joannemcpeake evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT ruthforrest evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT antoinbreslin evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT fionamacgregor evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation AT alisonoprey evaluationofmedicationchangesfollowingseverecovid19infectionamulticentreevaluation |